Mice	NNS	NP	B-KP 0 4	[1]	[4]	CAPITALIZED	allAlpha
bearing	VBG	VP	I-KP 5 12	[2]	[7]	LOWERCASE	allAlpha
the	DT	OTHER	I-KP 13 16	[3]	[3]	LOWERCASE	allAlpha
orthotopic	JJ	NP	I-KP 17 27	[4]	[10]	LOWERCASE	allAlpha
model	NN	NP	I-KP 28 33	[5]	[5]	LOWERCASE	allAlpha
were	VBD	VP	O 34 38	[6]	[4]	LOWERCASE	allAlpha
treated	VBN	VP	O 39 46	[7]	[7]	LOWERCASE	allAlpha
starting	VBG	VP	O 47 55	[8]	[8]	LOWERCASE	allAlpha
from	IN	PP	O 56 60	[9]	[4]	LOWERCASE	allAlpha
day	NN	NP	O 61 64	[10]	[3]	LOWERCASE	allAlpha
21	CD	OTHER	O 65 67	[11]	[2]	LOWERCASE	ContainSymbol
after	IN	PP	O 68 73	[12]	[5]	LOWERCASE	allAlpha
NB	NN	NP	O 74 76	[13]	[2]	CAPITALIZED	allAlpha
cell	NN	NP	O 77 81	[14]	[4]	LOWERCASE	allAlpha
implant;	NN	NP	O 82 90	[15]	[8]	LOWERCASE	ContainSymbol
mice	NNS	NP	B-KP 91 95	[16]	[4]	LOWERCASE	allAlpha
with	IN	OTHER	I-KP 96 100	[17]	[4]	LOWERCASE	allAlpha
the	DT	OTHER	I-KP 101 104	[18]	[3]	LOWERCASE	allAlpha
pseudo-metastatic	JJ	NP	I-KP 105 122	[19]	[17]	LOWERCASE	ContainSymbol
model	NN	NP	I-KP 123 128	[20]	[5]	LOWERCASE	allAlpha
received	VBD	VP	O 129 137	[21]	[8]	LOWERCASE	allAlpha
the	DT	OTHER	O 138 141	[22]	[3]	LOWERCASE	allAlpha
first	JJ	NP	O 142 147	[23]	[5]	LOWERCASE	allAlpha
treatment	NN	NP	O 148 157	[24]	[9]	LOWERCASE	allAlpha
4h	NN	NP	O 158 160	[25]	[2]	LOWERCASE	ContainSymbol
after	IN	PP	O 161 166	[26]	[5]	LOWERCASE	allAlpha
NB	NN	NP	O 167 169	[27]	[2]	CAPITALIZED	allAlpha
cell	NN	NP	O 170 174	[28]	[4]	LOWERCASE	allAlpha
injection.	NN	NP	O 175 184	[29]	[10]	LOWERCASE	ContainSymbol

These	DT	OTHER	B-KP 186 191	[1]	[5]	CAPITALIZED	allAlpha
therapeutic	JJ	NP	I-KP 192 203	[2]	[11]	LOWERCASE	allAlpha
schedules	NNS	NP	I-KP 204 213	[3]	[9]	LOWERCASE	allAlpha
were	VBD	VP	O 214 218	[4]	[4]	LOWERCASE	allAlpha
designed	VBN	VP	O 219 227	[5]	[8]	LOWERCASE	allAlpha
to	TO	OTHER	O 228 230	[6]	[2]	LOWERCASE	allAlpha
test	VB	VP	B-KP 231 235	[7]	[4]	LOWERCASE	allAlpha
the	DT	OTHER	I-KP 236 239	[8]	[3]	LOWERCASE	allAlpha
effects	NNS	NP	I-KP 240 247	[9]	[7]	LOWERCASE	allAlpha
of	IN	PP	O 248 250	[10]	[2]	LOWERCASE	allAlpha
our	PRP$	OTHER	B-KP 251 254	[11]	[3]	LOWERCASE	allAlpha
targeted	VBN	VP	I-KP 255 263	[12]	[8]	LOWERCASE	allAlpha
formulations	NNS	NP	I-KP 264 276	[13]	[12]	LOWERCASE	allAlpha
against	IN	OTHER	O 277 284	[14]	[7]	LOWERCASE	allAlpha
both	CC	OTHER	O 285 289	[15]	[4]	LOWERCASE	allAlpha
established	JJ	OTHER	O 290 301	[16]	[11]	LOWERCASE	allAlpha
and	CC	OTHER	O 302 305	[17]	[3]	LOWERCASE	allAlpha
pseudo-metastatic	JJ	NP	O 306 323	[18]	[17]	LOWERCASE	ContainSymbol
preclinical	JJ	NP	B-KP 324 335	[19]	[11]	LOWERCASE	allAlpha
models	NNS	NP	I-KP 336 342	[20]	[6]	LOWERCASE	allAlpha
of	IN	PP	O 343 345	[21]	[2]	LOWERCASE	allAlpha
human	JJ	NP	O 346 351	[22]	[5]	LOWERCASE	allAlpha
NB,	NN	NP	O 352 354	[23]	[3]	CAPITALIZED	ContainSymbol
as	IN	OTHER	O 356 358	[24]	[2]	LOWERCASE	allAlpha
described	VBN	VP	O 359 368	[25]	[9]	LOWERCASE	allAlpha
[16,19].	NN	NP	O 369 376	[26]	[8]	LOWERCASE	ContainSymbol

Animals	NNS	NP	B-KP 378 385	[1]	[7]	CAPITALIZED	allAlpha
were	VBD	VP	O 386 390	[2]	[4]	LOWERCASE	allAlpha
treated	VBN	VP	O 391 398	[3]	[7]	LOWERCASE	allAlpha
i.v.	RB	OTHER	O 399 402	[4]	[4]	LOWERCASE	ContainSymbol

once	RB	OTHER	O 404 408	[1]	[4]	LOWERCASE	allAlpha
a	DT	OTHER	O 409 410	[2]	[1]	LOWERCASE	allAlpha
week	NN	NP	O 411 415	[3]	[4]	LOWERCASE	allAlpha
for	IN	OTHER	O 416 419	[4]	[3]	LOWERCASE	allAlpha
3	CD	OTHER	O 420 421	[5]	[1]	LOWERCASE	ContainSymbol
weeks	NNS	NP	O 422 427	[6]	[5]	LOWERCASE	allAlpha
with	IN	PP	O 428 432	[7]	[4]	LOWERCASE	allAlpha
untargeted	JJ	NP	B-KP 433 443	[8]	[10]	LOWERCASE	allAlpha
(SL[DXR])	NN	NP	O 444 453	[9]	[9]	LOWERCASE	ContainSymbol
or	CC	OTHER	O 454 456	[10]	[2]	LOWERCASE	allAlpha
peptide-targeted	JJ	NP	B-KP 457 473	[11]	[16]	LOWERCASE	ContainSymbol
SL[DXR]	NN	NP	I-KP 474 481	[12]	[7]	CAPITALIZED	ContainSymbol
(5mg/kg).	NN	NP	O 482 490	[13]	[9]	LOWERCASE	ContainSymbol

Scrambled	VBN	VP	B-KP 492 501	[1]	[9]	CAPITALIZED	allAlpha
peptide-functionalized	JJ	NP	I-KP 502 524	[2]	[22]	LOWERCASE	ContainSymbol
liposomes	NNS	NP	I-KP 525 534	[3]	[9]	LOWERCASE	allAlpha
were	VBD	VP	O 535 539	[4]	[4]	LOWERCASE	allAlpha
used	VBN	VP	O 540 544	[5]	[4]	LOWERCASE	allAlpha
as	IN	OTHER	O 545 547	[6]	[2]	LOWERCASE	allAlpha
a	DT	OTHER	O 548 549	[7]	[1]	LOWERCASE	allAlpha
control,	NN	NP	O 550 557	[8]	[8]	LOWERCASE	ContainSymbol
and	CC	OTHER	O 559 562	[9]	[3]	LOWERCASE	allAlpha
in	IN	OTHER	O 563 565	[10]	[2]	LOWERCASE	allAlpha
every	DT	OTHER	O 566 571	[11]	[5]	LOWERCASE	allAlpha
experiment	NN	NP	O 572 582	[12]	[10]	LOWERCASE	allAlpha
a	DT	OTHER	O 583 584	[13]	[1]	LOWERCASE	allAlpha
group	NN	NP	O 585 590	[14]	[5]	LOWERCASE	allAlpha
of	IN	PP	O 591 593	[15]	[2]	LOWERCASE	allAlpha
control	NN	NP	O 594 601	[16]	[7]	LOWERCASE	allAlpha
mice	NNS	NP	O 602 606	[17]	[4]	LOWERCASE	allAlpha
received	VBD	VP	O 607 615	[18]	[8]	LOWERCASE	allAlpha
HEPES-buffered	JJ	NP	B-KP 616 630	[19]	[14]	CAPITALIZED	ContainSymbol
saline.	NN	NP	I-KP 631 637	[20]	[7]	LOWERCASE	ContainSymbol

Survival	NN	NP	B-KP 639 647	[1]	[8]	CAPITALIZED	allAlpha
times	NNS	NP	I-KP 648 653	[2]	[5]	LOWERCASE	allAlpha
were	VBD	VP	O 654 658	[3]	[4]	LOWERCASE	allAlpha
used	VBN	VP	O 659 663	[4]	[4]	LOWERCASE	allAlpha
as	IN	OTHER	O 664 666	[5]	[2]	LOWERCASE	allAlpha
the	DT	OTHER	O 667 670	[6]	[3]	LOWERCASE	allAlpha
main	JJ	NP	O 671 675	[7]	[4]	LOWERCASE	allAlpha
criterion	NN	NP	O 676 685	[8]	[9]	LOWERCASE	allAlpha
for	IN	OTHER	O 686 689	[9]	[3]	LOWERCASE	allAlpha
determining	VBG	VP	B-KP 690 701	[10]	[11]	LOWERCASE	allAlpha
treatment	NN	NP	I-KP 702 711	[11]	[9]	LOWERCASE	allAlpha
efficacy.	NN	NP	I-KP 712 720	[12]	[9]	LOWERCASE	ContainSymbol

In	IN	OTHER	O 722 724	[1]	[2]	CAPITALIZED	allAlpha
the	DT	OTHER	O 725 728	[2]	[3]	LOWERCASE	allAlpha
orthotopic	JJ	NP	B-KP 729 739	[3]	[10]	LOWERCASE	allAlpha
model,	NN	NP	I-KP 740 745	[4]	[6]	LOWERCASE	ContainSymbol
time-dependent	JJ	NP	B-KP 747 761	[5]	[14]	LOWERCASE	ContainSymbol
anti-tumor	JJ	NP	I-KP 762 772	[6]	[10]	LOWERCASE	ContainSymbol
activity	NN	NP	I-KP 773 781	[7]	[8]	LOWERCASE	allAlpha
was	VBD	VP	O 782 785	[8]	[3]	LOWERCASE	allAlpha
also	RB	OTHER	O 786 790	[9]	[4]	LOWERCASE	allAlpha
evaluated	VBN	VP	O 791 800	[10]	[9]	LOWERCASE	allAlpha
by	IN	PP	O 801 803	[11]	[2]	LOWERCASE	allAlpha
bioluminescence	NN	NP	O 804 819	[12]	[15]	LOWERCASE	allAlpha
imaging	NN	NP	O 820 827	[13]	[7]	LOWERCASE	allAlpha
(BLI)	NN	NP	O 828 833	[14]	[5]	LOWERCASE	ContainSymbol
and	CC	OTHER	O 834 837	[15]	[3]	LOWERCASE	allAlpha
X-ray	NN	NP	O 838 843	[16]	[5]	CAPITALIZED	ContainSymbol
analyses.	NN	NP	O 844 852	[17]	[9]	LOWERCASE	ContainSymbol

For	IN	OTHER	O 854 857	[1]	[3]	CAPITALIZED	allAlpha
this	DT	OTHER	O 858 862	[2]	[4]	LOWERCASE	allAlpha
purpose,	NN	NP	O 863 870	[3]	[8]	LOWERCASE	ContainSymbol
the	DT	OTHER	B-KP 872 875	[4]	[3]	LOWERCASE	allAlpha
GI-LI-N	NN	NP	I-KP 876 883	[5]	[7]	CAPITALIZED	ContainSymbol
cell	NN	NP	I-KP 884 888	[6]	[4]	LOWERCASE	allAlpha
line	NN	NP	I-KP 889 893	[7]	[4]	LOWERCASE	allAlpha
was	VBD	VP	O 894 897	[8]	[3]	LOWERCASE	allAlpha
infected	VBN	VP	B-KP 898 906	[9]	[8]	LOWERCASE	allAlpha
with	IN	PP	O 907 911	[10]	[4]	LOWERCASE	allAlpha
a	DT	OTHER	O 912 913	[11]	[1]	LOWERCASE	allAlpha
retrovirus	NN	NP	O 914 924	[12]	[10]	LOWERCASE	allAlpha
expressing	VBG	VP	O 925 935	[13]	[10]	LOWERCASE	allAlpha
the	DT	OTHER	O 936 939	[14]	[3]	LOWERCASE	allAlpha
firefly	JJ	NP	O 940 947	[15]	[7]	LOWERCASE	allAlpha
luciferase	NN	NP	O 948 958	[16]	[10]	LOWERCASE	allAlpha
gene,	NN	NP	O 959 963	[17]	[5]	LOWERCASE	ContainSymbol
as	RB	OTHER	O 965 967	[18]	[2]	LOWERCASE	allAlpha
previously	RB	OTHER	O 968 978	[19]	[10]	LOWERCASE	allAlpha
reported	VBD	VP	O 979 987	[20]	[8]	LOWERCASE	allAlpha
[17];	CD	OTHER	O 988 993	[21]	[5]	LOWERCASE	ContainSymbol
luciferase	NN	NP	B-KP 994 1004	[22]	[10]	LOWERCASE	allAlpha
activity	NN	NP	I-KP 1005 1013	[23]	[8]	LOWERCASE	allAlpha
of	IN	PP	O 1014 1016	[24]	[2]	LOWERCASE	allAlpha
retrovirally-transduced	JJ	NP	B-KP 1017 1040	[25]	[23]	LOWERCASE	ContainSymbol
cells	NNS	NP	I-KP 1041 1046	[26]	[5]	LOWERCASE	allAlpha
was	VBD	VP	O 1047 1050	[27]	[3]	LOWERCASE	allAlpha
visualized	VBN	VP	B-KP 1051 1061	[28]	[10]	LOWERCASE	allAlpha
in	FW	OTHER	O 1062 1064	[29]	[2]	LOWERCASE	allAlpha
vivo	FW	OTHER	O 1065 1069	[30]	[4]	LOWERCASE	allAlpha
by	IN	PP	O 1070 1072	[31]	[2]	LOWERCASE	allAlpha
BLI	NNP	NP	O 1073 1076	[32]	[3]	CAPITALIZED	allAlpha
(IVIS	NNP	NP	O 1077 1082	[33]	[5]	LOWERCASE	ContainSymbol
Caliper	NNP	NP	O 1083 1090	[34]	[7]	CAPITALIZED	allAlpha
Life	NNP	NP	O 1091 1095	[35]	[4]	CAPITALIZED	allAlpha
Sciences,	NNP	NP	O 1096 1104	[36]	[9]	CAPITALIZED	ContainSymbol
Hopkinton,	NNP	NP	O 1106 1115	[37]	[10]	CAPITALIZED	ContainSymbol
MA)	NNP	NP	O 1117 1120	[38]	[3]	CAPITALIZED	ContainSymbol
after	IN	OTHER	O 1121 1126	[39]	[5]	LOWERCASE	allAlpha
a	DT	OTHER	O 1127 1128	[40]	[1]	LOWERCASE	allAlpha
10min	JJ	NP	O 1129 1134	[41]	[5]	LOWERCASE	ContainSymbol
incubation	NN	NP	O 1135 1145	[42]	[10]	LOWERCASE	allAlpha
with	IN	PP	O 1146 1150	[43]	[4]	LOWERCASE	allAlpha
150Î¼g/mL	NN	NP	O 1151 1159	[44]	[8]	LOWERCASE	ContainSymbol
of	IN	PP	O 1160 1162	[45]	[2]	LOWERCASE	allAlpha
d-luciferin	NN	NP	B-KP 1163 1174	[46]	[11]	LOWERCASE	ContainSymbol
(Caliper	NN	NP	O 1175 1183	[47]	[8]	LOWERCASE	ContainSymbol
Life	NNP	NP	O 1184 1188	[48]	[4]	CAPITALIZED	allAlpha
Sciences),	NNP	NP	O 1189 1198	[49]	[10]	CAPITALIZED	ContainSymbol
as	IN	OTHER	O 1200 1202	[50]	[2]	LOWERCASE	allAlpha
described	VBN	VP	O 1203 1212	[51]	[9]	LOWERCASE	allAlpha
[17].	NN	NP	O 1213 1217	[52]	[5]	LOWERCASE	ContainSymbol

X-ray	NN	NP	O 1219 1224	[1]	[5]	CAPITALIZED	ContainSymbol
analysis	NN	NP	O 1225 1233	[2]	[8]	LOWERCASE	allAlpha
was	VBD	VP	O 1234 1237	[3]	[3]	LOWERCASE	allAlpha
superimposed	VBN	VP	O 1238 1250	[4]	[12]	LOWERCASE	allAlpha
to	TO	OTHER	O 1251 1253	[5]	[2]	LOWERCASE	allAlpha
the	DT	OTHER	O 1254 1257	[6]	[3]	LOWERCASE	allAlpha
luminescence	NN	NP	O 1258 1270	[7]	[12]	LOWERCASE	allAlpha
for	IN	OTHER	O 1271 1274	[8]	[3]	LOWERCASE	allAlpha
a	DT	OTHER	O 1275 1276	[9]	[1]	LOWERCASE	allAlpha
better	JJR	OTHER	O 1277 1283	[10]	[6]	LOWERCASE	allAlpha
visualization	NN	NP	O 1284 1297	[11]	[13]	LOWERCASE	allAlpha
of	IN	OTHER	O 1298 1300	[12]	[2]	LOWERCASE	allAlpha
the	DT	OTHER	O 1301 1304	[13]	[3]	LOWERCASE	allAlpha
tumors.	NN	NP	O 1305 1311	[14]	[7]	LOWERCASE	ContainSymbol

